Community participation in the ABI-007 study currently accounts for 40 percent of the total enrollment. Northeast Georgia Cancer Care, LLC in Athens, GA recently enrolled an additional patient in the Abraxis Study: ABI-007, the neoadjuvant trial of Trastuzumab in combination with dose-dense ABI007 (Abraxane) followed by Vinorelbine. The study is open at the following Georgia CORE research network sites:
- Dekalb Medical/Georgia Cancer Specialists
- Emory/Winship Cancer Institute
- Georgia Cancer Center for Excellence/Grady Health System
- Northeast Georgia Cancer Care
- Piedmont Hospital/Peachtree Hematology Oncology Consultants.